Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for +publisher:"University of Otago" +contributor:("Rosengren, Rhonda"). Showing records 1 – 16 of 16 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


University of Otago

1. Scandlyn, Marissa Jayne. Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model.

Degree: 2011, University of Otago

 Basal-like breast cancers are a subgroup of breast lesions that are triple-negative for the estrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor… (more)

Subjects/Keywords: EGCG; Breast cancer; Tamoxifen; Raloxifene; Curcumin

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Scandlyn, M. J. (2011). Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model. (Doctoral Dissertation). University of Otago. Retrieved from http://hdl.handle.net/10523/1688

Chicago Manual of Style (16th Edition):

Scandlyn, Marissa Jayne. “Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model. ” 2011. Doctoral Dissertation, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/1688.

MLA Handbook (7th Edition):

Scandlyn, Marissa Jayne. “Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model. ” 2011. Web. 17 Jan 2021.

Vancouver:

Scandlyn MJ. Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model. [Internet] [Doctoral dissertation]. University of Otago; 2011. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/1688.

Council of Science Editors:

Scandlyn MJ. Novel drug therapies for ER- basal-like breast cancer; preclinical evaluation in a xenograft model. [Doctoral Dissertation]. University of Otago; 2011. Available from: http://hdl.handle.net/10523/1688


University of Otago

2. Yadav, Babasaheb Dattatraya. Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers .

Degree: 2012, University of Otago

 Breast cancer is the most prevalent form of cancer diagnosed in women, and there continues to be limited drug treatment options for the ~30% of… (more)

Subjects/Keywords: breast cancer; curcumin analogs; apoptosis; angiogenesis

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Yadav, B. D. (2012). Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers . (Doctoral Dissertation). University of Otago. Retrieved from http://hdl.handle.net/10523/2290

Chicago Manual of Style (16th Edition):

Yadav, Babasaheb Dattatraya. “Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers .” 2012. Doctoral Dissertation, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/2290.

MLA Handbook (7th Edition):

Yadav, Babasaheb Dattatraya. “Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers .” 2012. Web. 17 Jan 2021.

Vancouver:

Yadav BD. Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers . [Internet] [Doctoral dissertation]. University of Otago; 2012. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/2290.

Council of Science Editors:

Yadav BD. Study of New Curcumin Analogs for the Treatment of Erα Negative Breast Cancers . [Doctoral Dissertation]. University of Otago; 2012. Available from: http://hdl.handle.net/10523/2290


University of Otago

3. Mazumder, Aloran. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .

Degree: 2013, University of Otago

 Background: Approximately 80% of prostate cancer patients undergoing hormone therapy progress within 12-18 months to a hormone insensitive form of the disease known as hormone… (more)

Subjects/Keywords: Therapy against prostate cancer; therapy; prostate; cancer

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mazumder, A. (2013). Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/4070

Chicago Manual of Style (16th Edition):

Mazumder, Aloran. “Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .” 2013. Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/4070.

MLA Handbook (7th Edition):

Mazumder, Aloran. “Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .” 2013. Web. 17 Jan 2021.

Vancouver:

Mazumder A. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . [Internet] [Masters thesis]. University of Otago; 2013. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/4070.

Council of Science Editors:

Mazumder A. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . [Masters Thesis]. University of Otago; 2013. Available from: http://hdl.handle.net/10523/4070


University of Otago

4. Tran, Khanh Bao. Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer .

Degree: 2012, University of Otago

 Approximately one in five breast cancer patients exhibits triple negative tumors that are characterized by the lack of estrogen receptor (ER), progesterone receptor and HER2.… (more)

Subjects/Keywords: cannabinoids; breast cancer; estrogen receptor

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Tran, K. B. (2012). Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/2292

Chicago Manual of Style (16th Edition):

Tran, Khanh Bao. “Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer .” 2012. Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/2292.

MLA Handbook (7th Edition):

Tran, Khanh Bao. “Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer .” 2012. Web. 17 Jan 2021.

Vancouver:

Tran KB. Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer . [Internet] [Masters thesis]. University of Otago; 2012. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/2292.

Council of Science Editors:

Tran KB. Synthetic Cannabinoids as a Novel Treatment for Triple Negative Breast Cancer . [Masters Thesis]. University of Otago; 2012. Available from: http://hdl.handle.net/10523/2292


University of Otago

5. Dzeyk, Julian. Raloxifene for the Treatment of Triple Negative Breast Cancer .

Degree: 2012, University of Otago

 Triple negative breast cancer (TNBC) represents a subgroup of mammary cancers associated with particularly poor prognosis as they are refractory to currently available targeted therapy… (more)

Subjects/Keywords: TNBC; triple negative; breast cancer; raloxifene; SERM; selective estrogen receptor modulator

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Dzeyk, J. (2012). Raloxifene for the Treatment of Triple Negative Breast Cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/2483

Chicago Manual of Style (16th Edition):

Dzeyk, Julian. “Raloxifene for the Treatment of Triple Negative Breast Cancer .” 2012. Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/2483.

MLA Handbook (7th Edition):

Dzeyk, Julian. “Raloxifene for the Treatment of Triple Negative Breast Cancer .” 2012. Web. 17 Jan 2021.

Vancouver:

Dzeyk J. Raloxifene for the Treatment of Triple Negative Breast Cancer . [Internet] [Masters thesis]. University of Otago; 2012. [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/2483.

Council of Science Editors:

Dzeyk J. Raloxifene for the Treatment of Triple Negative Breast Cancer . [Masters Thesis]. University of Otago; 2012. Available from: http://hdl.handle.net/10523/2483


University of Otago

6. Nhemachena, Tafadzwa. The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells .

Degree: University of Otago

 Background: Ovarian cancer is the most lethal gynecological malignancy among women, and there is limited treatment. The search for effective therapies for ovarian cancer has… (more)

Subjects/Keywords: curcumin; ovarian cancer; RL112; SKOV3

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Nhemachena, T. (n.d.). The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/7714

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Nhemachena, Tafadzwa. “The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/7714.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Nhemachena, Tafadzwa. “The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Nhemachena T. The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/7714.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Nhemachena T. The Cytotoxic Mechanism of RL112 in Ovarian Cancer Cells . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/7714

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

7. Chen, Shuli. Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer .

Degree: University of Otago

 Prostate cancer, a hormonally driven and dependent malignancy, is a leading cause of cancer-related deaths in men. Hormonal therapy including surgical castration and medical/chemical castration… (more)

Subjects/Keywords: Hormone-Refractory Prostate Cancer; curcumin analogues; in vitro

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Chen, S. (n.d.). Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/7588

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Chen, Shuli. “Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/7588.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Chen, Shuli. “Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Chen S. Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/7588.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Chen S. Anticancer Potential of Novel Curcumin Analogues towards Hormone-Refractory Prostate Cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/7588

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

8. Martey, Orleans Nii Korley. Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer .

Degree: University of Otago

 Patients diagnosed with triple negative breast cancer (TNBC) have a poor prognosis, due in part to the lack of targeted treatment options. In the search… (more)

Subjects/Keywords: xenograft model; molecular target; SMA-RL71; nanomedicine; GNL1

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Martey, O. N. K. (n.d.). Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer . (Doctoral Dissertation). University of Otago. Retrieved from http://hdl.handle.net/10523/8540

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Martey, Orleans Nii Korley. “Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer .” Doctoral Dissertation, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/8540.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Martey, Orleans Nii Korley. “Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Martey ONK. Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer . [Internet] [Doctoral dissertation]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/8540.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Martey ONK. Development of SMA-RL71 as a nanomedicine for the treatment of triple negative breast cancer . [Doctoral Dissertation]. University of Otago; Available from: http://hdl.handle.net/10523/8540

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

9. Pritchard, Tara Cheree. SMA-raloxifene for the management of castrate-resistant prostate cancer .

Degree: University of Otago

 Castrate-resistant prostate cancer (CRPC) has a poor prognosis, and these tumours are refractory to conventional androgen deprivation therapy. In addition to androgen, oestrogen alone or… (more)

Subjects/Keywords: castrate-resistant prostate cancer; raloxifene; nanomedicine; biodistribution

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pritchard, T. C. (n.d.). SMA-raloxifene for the management of castrate-resistant prostate cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/5683

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Pritchard, Tara Cheree. “SMA-raloxifene for the management of castrate-resistant prostate cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/5683.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Pritchard, Tara Cheree. “SMA-raloxifene for the management of castrate-resistant prostate cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Pritchard TC. SMA-raloxifene for the management of castrate-resistant prostate cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/5683.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Pritchard TC. SMA-raloxifene for the management of castrate-resistant prostate cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/5683

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

10. Gwavava, Patrick. Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro .

Degree: University of Otago

 Background: Ovarian cancer is the most lethal gynaecological cancer in women. Nearly a quarter of a million women are newly diagnosed globally, with up to… (more)

Subjects/Keywords: Ovarian; cancer; Heterocyclic; Cyclohexanone; Analogues; Inhibit Growth; in-vitro; RL112; RL117; gynaecological cancer; second generation; SKOV-3; OVCAR-3; Cytotoxicity; AKT; ERK; NF-κB

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Gwavava, P. (n.d.). Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/5777

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Gwavava, Patrick. “Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/5777.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Gwavava, Patrick. “Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Gwavava P. Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/5777.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Gwavava P. Heterocyclic Cyclohexanone Curcumin Analogues Inhibit Growth of Ovarian Cancer Cells, in-vitro . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/5777

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

11. Palmer, Hannah. Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer .

Degree: University of Otago

 Prostate cancer is the second most diagnosed cancer worldwide and accounts for 15% of all cancer in men. Localised prostate cancer, contained within the capsule… (more)

Subjects/Keywords: raloxifene; castrate-resistant; prostate; cancer; curcumin; RL91; intraprostatic

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Palmer, H. (n.d.). Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/6046

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Palmer, Hannah. “Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/6046.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Palmer, Hannah. “Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Palmer H. Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/6046.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Palmer H. Using Raloxifene and the Curcumin Derivative, RL91, for the Treatment of Castrate Resistant Prostate Cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/6046

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

12. Wang, Yue. Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines .

Degree: University of Otago

 Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype characterised by a poor outcome when compared to other breast cancers. The lack of… (more)

Subjects/Keywords: Triple negative breast cancer; RNA sequencing; Curcumin analogs; Micelles; PI3K/Akt/mTOR pathway; MAPK pathway; JAK-STAT pathway

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Wang, Y. (n.d.). Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/6447

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Wang, Yue. “Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/6447.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Wang, Yue. “Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Wang Y. Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/6447.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Wang Y. Identification of differentially expressed genes in response to treatment with RL71 and SMA-RL71 in triple negative breast cancer cell lines . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/6447

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

13. Sundararajan, Vignesh. Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer .

Degree: University of Otago

 Triple negative breast cancer (TNBC) is a subtype of ER (-) cancer that currently has no treatment options. A novel drug formulation of the most… (more)

Subjects/Keywords: Breast; cancer; EPR; curcumin; analogue; nanomicelle; SMA-RL71

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Sundararajan, V. (n.d.). Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/5410

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Sundararajan, Vignesh. “Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/5410.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Sundararajan, Vignesh. “Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Sundararajan V. Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/5410.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Sundararajan V. Evaluation of SMA-RL71, a curcumin analogue nanomicelle as a drug in xenograft models of triple negative breast cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/5410

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

14. Shakil, Md Salman. Novel drug development for KRAS-mutated non-small cell lung cancer .

Degree: University of Otago

 Lung cancer is the leading cause of cancer-related death among both men and women and non-small cell lung cancer (NSCLC) accounts for 85 to 88%… (more)

Subjects/Keywords: Novel drug; KRAS; NSCLC; Hydroxythiopyridone derivatives

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Shakil, M. S. (n.d.). Novel drug development for KRAS-mutated non-small cell lung cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/10446

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Shakil, Md Salman. “Novel drug development for KRAS-mutated non-small cell lung cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/10446.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Shakil, Md Salman. “Novel drug development for KRAS-mutated non-small cell lung cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Shakil MS. Novel drug development for KRAS-mutated non-small cell lung cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/10446.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Shakil MS. Novel drug development for KRAS-mutated non-small cell lung cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/10446

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

15. Nathan, Risha Jasmine. Biosorption of heavy metals from drinking water using fruit and vegetable peels .

Degree: University of Otago

 Heavy metals in drinking water are a serious global concern and efforts are underway to develop sustainable decontamination techniques. The present project was developed with… (more)

Subjects/Keywords: Biosorption; Heavy Metal; Drinking water; Fruit peel; Vegetable peel; Multi ion; Adsorption; New Zealand

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Nathan, R. J. (n.d.). Biosorption of heavy metals from drinking water using fruit and vegetable peels . (Doctoral Dissertation). University of Otago. Retrieved from http://hdl.handle.net/10523/10166

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Nathan, Risha Jasmine. “Biosorption of heavy metals from drinking water using fruit and vegetable peels .” Doctoral Dissertation, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/10166.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Nathan, Risha Jasmine. “Biosorption of heavy metals from drinking water using fruit and vegetable peels .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Nathan RJ. Biosorption of heavy metals from drinking water using fruit and vegetable peels . [Internet] [Doctoral dissertation]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/10166.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Nathan RJ. Biosorption of heavy metals from drinking water using fruit and vegetable peels . [Doctoral Dissertation]. University of Otago; Available from: http://hdl.handle.net/10523/10166

Note: this citation may be lacking information needed for this citation format:
No year of publication.


University of Otago

16. Azam, Mayur. The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer .

Degree: University of Otago

 Histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous anticancer agents which consist of a hydrophobic capping group, linker region, and Zn 2+ chelating… (more)

Subjects/Keywords: HDAC; TNBC; Triple; Negative; Breast; Cancer; Curcumin; Pharmacology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Azam, M. (n.d.). The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/10129

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Chicago Manual of Style (16th Edition):

Azam, Mayur. “The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer .” Masters Thesis, University of Otago. Accessed January 17, 2021. http://hdl.handle.net/10523/10129.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

MLA Handbook (7th Edition):

Azam, Mayur. “The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer .” Web. 17 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Azam M. The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer . [Internet] [Masters thesis]. University of Otago; [cited 2021 Jan 17]. Available from: http://hdl.handle.net/10523/10129.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Council of Science Editors:

Azam M. The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer . [Masters Thesis]. University of Otago; Available from: http://hdl.handle.net/10523/10129

Note: this citation may be lacking information needed for this citation format:
No year of publication.

.